Guanidine Tablets 125 mg - Uses, Dose, Side effects

Guanidine is available as tablets for oral administration. It is used in the symptomatic treatment of Lambert-Eaton Myasthenic syndrome.

Guanidine Uses:

It is used to reduce fatigue and the symptoms of muscle weakness that are associated with Lambert Eaton myasthenic syndrome.
It is not indicated for the treatment of myasthenia gravis.

10-15 mg/kg/day orally in 3 or 4 divided doses initially.
The dose is then increased gradually to 35 mg/kg/day, or until toxicity develops.

Not indicated in children.

Use while breastfeeding

It can be excreted in breastmilk. The manufacturer does not recommend breastfeeding.

Adjustment in the dose has not been recommended in patients with kidney disease.

Adjustment in the dose has not been recommended in patients with liver disease by the manufacture

Cardiovascular:
- Atrial Fibrillation
- Cold Extremities
- Flushing
- Hypotension
- Palpitations
- Tachycardia
Central Nervous System:
- Ataxia
- Confusion
- Dizziness
- Emotional Lability
- Hallucination
- Irritability
- Jitteriness
- Mood Changes
- Nervousness
- Psychosis
Dermatologic:
- Diaphoresis
- Folliculitis
- Paresthesia
- Skin Rash
- Xeroderma
Gastrointestinal:
- Abdominal Cramps
- Anorexia
- Diarrhea
- Gastric Irritation
- Nausea
- Sore Throat
- Xerostomia
Genitourinary:
- Uremia
Hematologic & Oncologic:
- Anemia
- Bone-Marrow Depression
- Bruise
- Leukopenia
- Petechia
- Purpura
- Thrombocytopenia
Hepatic:
- Abnormal Hepatic Function Tests
Neuromuscular & Skeletal:
- Tremor
Renal:
- Increased Serum Creatinine
- Interstitial Nephritis (Acute Or Chronic)
- Renal Tubular Necrosis
Miscellaneous:
- Fever

Severe allergic reactions to any component of the drug or the drug itself

Suppression of bone marrow
- Its use has been linked to severe bone marrow suppression.
- Patients taking medications that suppress bonemarrow function should be advised to discontinue the use of the drug.
- Bone marrow suppression should be closely monitored.
- If bone marrow suppression is suspected, the treatment should be stopped immediately
Renal impairment
- Patients with impaired renal function should be cautious when taking the drug.

Guanidine: Drug Interaction

Risk Factor C (Monitor therapy)
Acetylcholinesterase Inhibitors	May enhance the adverse/toxic effect of Cholinergic Agonists.
Beta-Blockers	May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Management: Administer these agents in combination with caution, and monitor for conduction disturbances. Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.
Cimetropium	Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium.
Risk Factor D (Consider therapy modification)
Sincalide	Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.

It is administered orally without regard to meals.

It increases the release of Acetylcholine from the presynaptic nervous terminals, slowing down the depolarization/repolarization of cell membranes.
It is easily availableIntakeDistributed and has been aEliminating half-lifeBetween 7 and 8 hours